Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17229330 | 0.87 | HTR2A (0.43) | GSK3BCHEK1HTR2AGPR84DYRK1A | |
| SCHEMBL10271450 | 0.81 | GSK3B (0.51) | GSK3BMAP2K4TRPA1CHEK1MAT2A | |
| SCHEMBL25139869 | 0.78 | GSK3B (0.49) | GSK3BMAP2K4TRPA1CHEK1LMNA | |
| Hydrochloric Acid SCHEMBL20705285 | 0.77 | PRMT5 (0.47) | GSK3BMAP2K4TRPA1GPR84DAO | |
| SCHEMBL9963337 | 0.76 | KDM4E (0.47) | PDE3BPDE3AMEN1ALDH1A1KMT2A | |
| SCHEMBL905771 | 0.75 | HTR2A (0.55) | GSK3BCHEK1HTR2ADYRK1ACDC7 | |
| SCHEMBL16675892 | 0.75 | GSK3B (0.44) | GSK3BMAP2K4TRPA1CHEK1MAT2A | |
| SCHEMBL5635078 | 0.74 | GSK3B (0.42) | GSK3BMAP2K4TRPA1CHEK1MAT2A | |
| SCHEMBL1461282 | 0.74 | GSK3B (0.54) | GSK3BMAP2K4TRPA1MAT2AMAP4K4 | |
| SCHEMBL6612568 | 0.73 | GSK3B (0.56) | GSK3BMAP2K4MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-09 | — | — | US | disclosed |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2020-07-30 | — | — | US | disclosed |
| WO-2019028362-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| EP-2044062-A1 | INDOLE COMPOUNDS | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-2041086-A1 | INDOLE COMPOUNDS | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006790-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006790-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006793-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006793-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | KLKB1, KLK1, KLK5 | GSK3B 1813/4885MAP2K4 811/4885TRPA1 1989/4885 |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | GSK3B 1813/4885MAP2K4 811/4885TRPA1 1989/4885 |
| US-20100016371-A1 | Indole Compounds | IDO1, TPH1, IDO2 | GSK3B 252/4885MAP2K4 4375/4885TRPA1 1041/4885 |
| US-20090298866-A1 | Indole Compounds | IDO1, TPH1, IDO2 | GSK3B 203/4885MAP2K4 4022/4885TRPA1 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.